688488.SS Stock Analysis
68
Uncovered
Jiangsu Aidea Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Jiangsu Aidea Pharmaceutical Co., Ltd. engages in the production, supply, research and development of UTI raw materials. The company is headquartered in Yangzhou, Jiangsu and currently employs 379 full-time employees. The company went IPO on 2020-07-20. The firm is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The firm is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The firm's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The firm mainly distributes its products within domestic market.